Skip to main content
SpringerLink
Log in

Roflumilast appears to be cost saving in the UK among patients with very severe chronic obstructive pulmonary disease

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Van Nooten FE, Rutten-van Molken MP, Lindemann M, Sandtmann R.Cost-effectiveness of roflumilast in the UK: a 1-year study in patients with severe to very severe COPD. Value in Health 9: A260-A261 (plus poster) abstr. PRS3, No. 6, Nov-Dec 2006

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roflumilast appears to be cost saving in the UK among patients with very severe chronic obstructive pulmonary disease. Pharmacoecon. Outcomes News 518, 5 (2006). https://doi.org/10.2165/00151234-200605180-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605180-00014

Keywords

Search

Navigation